Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage
therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a
BTK inhibitor (BTKi) or BCL-2 inhibitor. The study will evaluate this combination in two
parallel cohorts and subjects will be assigned based on which class of novel agent-containing
regimen was used prior. Cohort A will consist of patients who progress after BTKi containing
regimens and Cohort B will consist of patients who progress after a BCL-2 containing regimen.
Subjects who progress on a regimen containing both a BTKi and a BCL-2 inhibitor, will be
enrolled in cohort B. Each cohort will be evaluated independently of each other.